logo
HHS carries out mass firings across health agencies after Supreme Court decision

HHS carries out mass firings across health agencies after Supreme Court decision

Yahoo15-07-2025
Thousands of employees across US federal health agencies received an email Monday afternoon telling them they were out of a job as of the close of business.
The firings were originally communicated April 1 for most of the included employees, but they'd been delayed as a legal battle played out. That culminated in a US Supreme Court decision July 8 that, the US Department of Health and Human Services said in the email, means the agency 'is now permitted to move forward with a portion of its [reduction in force].'
'You are hereby notified that you are officially separated from HHS at the close of business on July 14, 2025,' read Monday's notice to dismissed HHS employees, according to copies obtained by CNN. 'Thank you for your service to the American people.'
'HHS previously announced our plans to transform this department to Make America Healthy Again and we intend to do just that,' HHS spokesperson Andrew Nixon said in an email to CNN after the Supreme Court's ruling last week.
In a reorganization announced March 27, HHS eliminated 10,000 employees across agencies including the US Food and Drug Administration, the US Centers for Disease Control and Prevention and the US National Institutes of Health; some have since gotten their jobs back, but the number losing employment Monday is in the thousands, a spokesperson for the agency confirmed.
Some of those 10,000, though, are protected at least temporarily under a different court case, New York v. Kennedy, and are not being separated immediately, the spokesperson said. That includes employees at six units of the CDC — the National Center for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention; the National Center for Environmental Health; the Division of Reproductive Health; the National Institute for Occupational Safety and Health; the Office on Smoking and Health; and the National Center for Birth Defects and Development Disabilities — the Center for Tobacco Products at the FDA; the Office of Head Start; and the Division of Data and Technical Analysis under the Assistant Secretary for Planning and Evaluation.
'All employees previously notified on April 1 have been separated, except for those' to whom the temporary protection in New York v. Kennedy applies, the HHS spokesperson said.
In that case, Judge Melissa DuBose of US District Court in Rhode Island granted a preliminary injunction request this month from a coalition of 19 states and the District of Columbia to halt the March 27 reorganization plan.
Last week, the administration asked DuBose to narrow her ruling to the divisions cited by the HHS spokesperson, but the judge has yet to rule on that request.
The layoffs will probably be challenged in court given that many HHS workers are still protected by DuBose's order, but the agency could argue that the Supreme Court ruling allows it to reduce staff, said Michael Fallings, a managing partner at Tully Rinckey who specializes in federal employment law.
Also Monday, the Supreme Court allowed the Trump administration to proceed with mass layoffs at another agency – the Department of Education – for now. The ruling came in a lawsuit filed by a teachers union, school districts, states and education groups.
Within two hours of that decision, the department sent notices to employees indicating that it's immediately resuming its plans and that the workers would be let go on August 1.
'They seem to be emboldened by the recent Supreme Court decisions that have been green-lighting the Trump administration's actions that other courts have stayed,' said Andrew Twinamatsiko, a director of the Center for Health Policy and the Law at the O'Neill Institute at Georgetown University, of HHS proceeding with the layoffs.
In last week's Supreme Court ruling, the justices allowed federal agencies to proceed with their reduction-in-force, or RIF, plans, putting on hold a lower court order that had temporarily blocked President Donald Trump from taking those steps without approval from Congress.
But the justices noted that 'we express no view on the legality of any Agency RIF and Reorganization Plan,' leaving open the possibility that it could rule against a specific agency's layoff plan in the future if the reductions appeared to make it impossible for the department to carry out its obligation under the law.
Filed by a coalition of more than a dozen unions, nonprofits and local governments, that case stemmed from an executive order Trump signed in mid-February that kicked off the process of significantly reducing the size of federal agencies.
CNN's John Fritze, Devan Cole and Sunlen Serfaty contributed to this report.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Vibrant Gastro Announces Federal Supply Schedule Contract Approval, Expanding Access to Veterans and Federal Health Patients
Vibrant Gastro Announces Federal Supply Schedule Contract Approval, Expanding Access to Veterans and Federal Health Patients

Yahoo

time30 minutes ago

  • Yahoo

Vibrant Gastro Announces Federal Supply Schedule Contract Approval, Expanding Access to Veterans and Federal Health Patients

About Vibrant® Austin, TX, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Vibrant Gastro, inventor of the Vibrant® System, today announced that its FDA‑cleared, drug‑free treatment for chronic idiopathic constipation (CIC) is now available on the General Services Administration's (GSA) Federal Supply Schedule (FSS) contract. This milestone expands access to care for millions of Americans served by the U.S. Department of Veterans Affairs (VA), Department of Defense, TRICARE, Indian Health Service, and other federal and state entities. 'Chronic idiopathic constipation is more than a medical condition - it impacts daily life, dignity, and independence,' said Asaf Bar, CEO of Vibrant Gastro. 'By offering Vibrant® through the FSS contract, we are proud to help our nation's Veterans, military families, and other federal beneficiaries gain access to a novel, safe, and effective treatment option.' CIC affects 1 in 10 American adults, with women and people of color disproportionately impacted. Many patients struggle with existing treatments due to side effects such as sudden, unpredictable diarrhea. Vibrant® works differently: an ingestible drug‑free capsule is programmed to help restore the colon's natural rhythm, providing more predictable relief, by gently vibrating inside the colon. In clinical studies, Vibrant® was shown to significantly improve symptoms with a low rate of side effects (1.2% diarrhea vs. 16% with leading traditional prescription medications) and no drug‑drug interactions. With FSS contract approval, Vibrant® is now available to eligible patients across federal and commercial plans, enabling access to more than 60 million lives nationwide. To learn more about the Vibrant System, visit or contact us at service@ or 866‑359‑7532. About Vibrant GastroVibrant Gastro is a health‑tech company pioneering drug free therapies for gastrointestinal disorders. Its first‑in‑class product, the Vibrant® System, is a prescription vibrating capsule that provides a non‑pharmacological treatment for chronic idiopathic constipation. FDA‑cleared for adults with CIC who have not responded to standard laxatives, Vibrant delivers an alternative for patients seeking safe, effective relief. Attachment About Vibrant® CONTACT: Asaf Bar Vibrant Gastro 866-359-7532 asaf.b@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Boehringer and Click Therapeutics' investigational prescription digital therapeutic CT-155 meets primary endpoint in CONVOKE study for negative symptoms in schizophrenia
Boehringer and Click Therapeutics' investigational prescription digital therapeutic CT-155 meets primary endpoint in CONVOKE study for negative symptoms in schizophrenia

Yahoo

time30 minutes ago

  • Yahoo

Boehringer and Click Therapeutics' investigational prescription digital therapeutic CT-155 meets primary endpoint in CONVOKE study for negative symptoms in schizophrenia

Boehringer Ingelheim library CT-155 showed a reduction in experiential negative symptoms as an adjunct to standard of care antipsychotic therapy from baseline to week 16, as measured by CAINS-MAP. CT-155 is an investigational prescription digital therapeutic being evaluated to target negative symptoms of schizophrenia in a registrational randomized clinical trial.1,2 Often underappreciated and less recognized, negative symptoms impact more than half of people living with schizophrenia.3 Ingelheim, Germany / Ridgefield, Connecticut / New York, New York Boehringer Ingelheim and Click Therapeutics today announced that the pivotal Phase III CONVOKE study (NCT05838625) of CT-155 (BI 3972080), an investigational prescription digital therapeutic (PDT), met its primary endpoint. The randomized, double-blind, controlled study investigated the effectiveness and safety of CT-155 versus a digital control app as an adjunct to standard of care antipsychotic therapy in people diagnosed and living with schizophrenia experiencing negative symptoms.1 The study's primary endpoint was change in experiential negative symptoms from baseline to week 16 as measured by the Clinical Assessment Interview for Negative Symptoms, Motivation and Pleasure Scale (CAINS-MAP).1 In the CONVOKE study, CT-155 was well tolerated and demonstrated a favorable safety profile consistent with past studies. 'Today's positive results from the CT-155 pivotal trial are an important moment for people living with the negative symptoms of schizophrenia,' said Emmanuelle Clerisme-Beaty, Medical Director US, SVP Medicine, Boehringer Ingelheim Pharmaceuticals, Inc. 'Although treatments are being used to help manage negative symptoms, there are no U.S. regulatory authority-approved treatments indicated for the negative symptoms of schizophrenia to date. This is one of the largest unmet needs for these patients and those who care for them. We are proud to work in partnership with multiple stakeholders and innovative partners like Click Therapeutics on this journey.' Approximately 2.8 million adults in the U.S. live with schizophrenia, which places a profound burden on individuals, families and society.4,5 About 60% of people living with schizophrenia experience negative symptoms.3 'Findings from CONVOKE provide the first Phase III evidence supporting the potential of a prescription digital therapeutic as an adjunct to standard of care antipsychotic therapy to treat a core element of schizophrenia,' said Shaheen Lakhan, MD, PhD, FAAN, chief medical and scientific officer of Click Therapeutics. 'The observed clinical benefit on experiential negative symptoms in this study, without additional known safety concerns, marks a critical advancement in understanding how we might address this long unmet need.' Detailed results will be presented during the Novel Therapeutics Symposium on Monday, October 13 at the 38th Annual European College of Neuropsychopharmacology (ECNP) Congress being held in Amsterdam, The Netherlands. About CT-155 CT-155 (BI 3972080) is an investigational prescription digital therapeutic that aims to provide interactive psychosocial intervention techniques as an adjunct to standard antipsychotic therapy to people living with schizophrenia experiencing negative symptoms.1,2,6 CT-155 is being developed by Click Therapeutics, Inc. and Boehringer Ingelheim.1,6 In 2024, CT-155 was granted Breakthrough Device designation by regulatory authorities in the U.S.6 CT-155 has not been authorized by any regulatory authorities. Safety and effectiveness have not been established by any regulatory authority. About the CONVOKE study CONVOKE (NCT05838625) was a Phase III, multicenter, randomized, double-blind, 16-week study evaluating the efficacy and safety of CT-155 versus a digital control app as an adjunct to standard of care antipsychotic therapy in people diagnosed and living with schizophrenia and experiential negative symptoms.1 The study enrolled adults and late adolescents with schizophrenia who were stable on antipsychotic medication.1 The primary endpoint evaluated improvement in experiential negative symptoms as an adjunct to standard of care as measured by changes from baseline to week 16 in the Clinical Assessment Interview for Negative Symptoms, Motivation and Pleasure Scale (CAINS-MAP).1 Other endpoints include: change from baseline in CAINS-MAP at week 8; change from baseline in CAINS expressivity scale (CAINS-EXP) at weeks 8 and 16; change from baseline in positive symptoms measured by the Positive and Negative Syndrome Scale (PANSS) at weeks 8 and 16; change from baseline in social functioning measured by the Personal and Social Performance Scale (PSP) at weeks 8 and 16; and patient global impression of improvement measured by Patient Global Impression of Improvement Scale (PGI-I) at weeks 8 and 16.1 About prescription digital therapeutics (PDTs) PDTs are software-based interventions prescribed by healthcare professionals and installed on smartphones to help address behavioral dimensions of diseases and conditions.7,8 PDTs are designed to be convenient, user friendly and accessible at all times of day, potentially helping to address barriers to care such as costs and mental health provider shortages—a shortage that is particularly exacerbated in rural areas.7,8,9,10 Additionally, the care provided can be patient-centered and flexible, to meet the patient where they are in their own treatment journey.7,8 About negative symptoms of schizophrenia Schizophrenia affects approximately 24 million people worldwide, and about 60% of people living with the condition experience negative symptoms.3,4 Negative symptoms are one of the three core symptoms domains of schizophrenia, along with positive symptoms and cognitive impairment.11 Negative symptoms include both experiential or expressive symptoms.3,12 Experiential negative symptoms include lack of motivation (avolition), decreased social interactions (asociality) and diminished ability to feel pleasure (anhedonia).3,12 Expressive negative symptoms refer to decreased expression of emotions (blunted affect) and reduction in speaking (alogia).3,12 In a U.S. single retrospective analysis, schizophrenia was associated with a significant economic burden, accounting for over $60 billion in direct healthcare costs in 2019.13 In another U.S. retrospective cohort study assessing claims from 2016-2023, the economic burden was greater for those who experience negative symptoms than those without negative symptoms, as these symptoms were associated with higher healthcare resource utilization, including higher costs, more outpatient/inpatient visits and longer hospitalizations.14 Although treatments are being used to help manage negative symptoms, there are no U.S. regulatory authority-approved treatments indicated for negative symptoms of schizophrenia to date.3,6 About Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at Boehringer About Click Therapeutics Click Therapeutics, Inc. develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. Operating at the intersection of biology and technology, Click uses a proprietary platform-based approach to therapeutic development that leverages patient-centric design principles and innovative AI-based technologies to deliver a unique combination of engagement and clinical outcomes. Digital therapeutics on Click's platform are regulated, clinically validated prescription mobile applications that are being developed to address diverse areas of therapeutic need, including indications in psychiatry, neurology, oncology, immunology, and cardiometabolic diseases. Click's commitment to advancing digital medicine means they continually improve their platform technologies, ensuring they stay at the forefront of cognitive, behavioral, and neuromodulatory therapeutic innovation, to achieve the best possible outcomes for patients. Their diverse team of innovators—spanning clinicians, researchers, technologists, designers and more—works together to create cutting-edge digital therapeutics, united in the mission to transform patient care. For more information, visit and connect with Click on LinkedIn. Media Contacts Boehringer Ingelheim: Tereza Urbankova Senior Media Relations Manager press@ +49 (6132) 77-184817 Click Therapeutics: Emily Flint pr@ +1 (978) 412-7273 References Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia (CONVOKE). Available from: Accessed August 2025. CT-155 (BI 3972080): Prescription digital therapeutic. Boehringer Ingelheim. Available from: Accessed August 2025. Correll CU, Schooler NR. Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment. Neuropsychiatr Dis Treat. 2020;16:519–534. Schizophrenia. WHO. Available from: Accessed August 2025. Schizophrenia Fact Sheet. Treatment Advocacy Center. Available from: Accessed August 2025. Boehringer Ingelheim and Click Therapeutics receive FDA breakthrough device designation for schizophrenia prescription digital therapeutic. Boehringer Ingelheim. Available from: Accessed August 2025. Phan P, Mitragotri S, Zhao Z. Digital therapeutics in the clinic. Bioeng Transl Med. May 2023;8(4):e10536. DTx Value Assessment & Integration Guide. DTx Alliance. Available from : Accessed August 2025. Health Resources and Services Administration. Health Workforce Shortage Areas. Available from: Accessed August 2025. Health Resources and Services Administration. State of the Behavioral Health Workforce, 2024. Available from: Accessed August 2025. Hany M, Rizvi A. Schizophrenia. StatPearls [Internet]. Available from: Accessed August 2025. Llerena K, Reddy LF, Kern RS. The role of experiential and expressive negative symptoms on job obtainment and work outcome in individuals with schizophrenia. Schizophr Res. 2018;192:148-153. Kadakia A, Catillon M, Fan Q, et al. The Economic Burden of Schizophrenia in the United States. J Clin Psychiatry. 2022 Oct 10;83(6):22m14458. Vaccaro J, Nili M, Xiang P, et al. Economic Burden Associated with Negative Symptoms Identified Through Natural Language Processing Among Patients with Schizophrenia in the United States. Schizophr Bull. 2025 Jun 3: Boehringer Ingelheim libraryError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

QinFlow Launches Advanced Fluid and Blood Warming Solution to Meet Critical Needs in ORs and ICUs
QinFlow Launches Advanced Fluid and Blood Warming Solution to Meet Critical Needs in ORs and ICUs

Yahoo

time30 minutes ago

  • Yahoo

QinFlow Launches Advanced Fluid and Blood Warming Solution to Meet Critical Needs in ORs and ICUs

Founded in 2009, QinFlow is a market leader in fluid thermoregulation solutions. PLANO, Texas, August 07, 2025--(BUSINESS WIRE)--Quality In Flow (QinFlow), a leading innovator in thermoregulation technology, has released the Warrior AC Station—its newest blood and fluid warming solution engineered to meet the demanding needs of Operating Rooms (ORs) and Intensive Care Units (ICUs). Part of the Warrior technology platform, the next-generation AC Station expands QinFlow's mission to deliver simple, high-performance, and versatile warming solutions across the entire continuum of care. Purpose-built for hospital-based resuscitation and infusion needs, the Warrior AC Station delivers warm blood and IV fluids in seconds—supporting rapid bolus resuscitation and a wide range of infusion methods. Its compact footprint, one-button operation, and compatibility with QinFlow's Compact Disposable Unit (CDU) make it ideal for any patient population in high-acuity environments. Unlike traditional warmers that are bulky and slow, the Warrior AC Station streamlines care delivery with unmatched speed, simplicity, and performance. Its shared consumable design supports seamless warming transitions across the care continuum—from prehospital to the OR and ICU—boosting efficiency and systemwide standardization. More than a warming device, the Warrior AC Station is a strategic solution that supports the Quadruple Aim of Healthcare: improving provider experience with intuitive operation; enhancing patient outcomes with immediate and precise warming; increasing operational efficiency through standardization and shared components; and lowering the cost of care by minimizing waste and simplifying logistics. "The Warrior AC Station reflects what clinicians value most in our platform—simple setup, immediate performance, and seamless integration into their workflows," said Ariel Katz, CEO of QinFlow. "We're equipping hospitals with a tool that simplifies delivery, elevates patient safety, and reduces waste and cost across every point of patient care." About QinFlow Founded in 2009, QinFlow (Quality in Flow) develops advanced blood and fluid warming systems designed to enhance patient safety, streamline care delivery, and eliminate cold blood and fluid administration. Trusted by leading hospitals, EMS agencies, trauma centers, and military teams, QinFlow's Warrior platform is redefining thermoregulation across the continuum of care. Discover how the Warrior AC Station can transform your OR and ICU workflows. Schedule a demo at for exclusive early adopter benefits. For more information, visit or contact info@ View source version on Contacts Lisa Owens, 210-601-6647 Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store